Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies
暂无分享，去创建一个
G. Acton | M. Davids | S. O'brien | J. Pinilla-Ibarz | D. Gladstone | J. Pagel | Jennifer R. Brown | W. Wierda | R. Furman | M. Shadman | P. Taverna | J. Fox | J. Sharman | J. Allan | Michael Y Choi | H. Yimer | D. Combs | R. Ward | K. Patel | M. Choi